Prostate cancer epidemiology

Lancet

Volumn 361, Issue 9360, 2003, Pages 859-864

  Grönberg, Henrik ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; FINASTERIDE; HORMONE; SELENIUM;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL; DIET; ETHNOLOGY; FAMILIAL CANCER; HEREDITY; HUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA;

EID: 0037426058     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)12713-4     Document Type: Review

References (91)

1. Parkin D.M., Whelan S.L., Ferlay J., Teppo L., Thomas D.B. Cancer incidence in five continents. 1997;IARC Sci Publ, Lyon. Vol VII.
2. Statistics Sweden. Cancer incidence in Sweden, 1999. Stockholm: Statistics Sweden, 2001.
3. Sakr W.A., Haas G.P., Cassin B.F., Pontes J.E., Crissman J.D. The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 150:1993;379-385.
4. Parkin D.M., Bray F.I., Devesa S.S. Cancer burden in the year 2000: the global picture. Eur J Cancer. 37:(suppl):2001;S4-66.
5. Wabinga H.R., Parkin D.M., Wabwire-Mangen F., Nambooze S. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. Br J Cancer. 82:2000;1585-1592.
6. Ogunbiyi J.O., Shittu O.B. Increased incidence of prostate cancer in Nigerians. J Natl Med Assoc. 91:1999;159-164.
7. Osegbe D.N. Prostate cancer in Nigerians: facts and nonfacts. J Urol. 157:1997;1340-1343.
8. Ries L.A.G., Eisner M., Kosary C.L., et al. SEER cancer statistics review, 973-999. 2002;National Cancer Institute, Bethesda.
9. Potosky A.L., Miller B.A., Albertsen P.C., Kramer B.S. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 273:1995;548-552.
10. Gronberg H., Bergh A., Damber J.E., Jonsson H., Lenner P., Angstrom T. Prostate cancer in northern Sweden: incidence, survival and mortality in relation to tumour grade. Acta Oncol. 33:1994;359-363.
11. Whittemore A.S., Wu A.H., Kolonel L.N., et al. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol. 141:1995;732-740.
12. Hayes R.B., Liff J.M., Pottern L.M., et al. Prostate cancer risk in US blacks and whites with a family history of cancer. Int J Cancer. 60:1995;361-364.
13. Monroe K.R., Yu M.C., Kolonel L.N., et al. Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med. 1:1995;827-829.
14. Gronberg H., Damber L., Damber J.E. Studies of genetic factors in prostate cancer in a twin population. J Urol. 152:1994;1484-1487.
15. Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer: analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 343:2000;78-85.
16. Page W.F., Braun M.M., Partin A.W., Caporaso N., Walsh P. Heredity and prostate cancer: a study of World War II veteran twins. Prostate. 33:1997;240-245.
17. Carter B.S., Beaty T.H., Steinberg G.D., Childs B., Walsh P.C. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA. 89:1992;3367-3371.
18. Gronberg H., Damber L., Damber J.E., Iselius L. Segregation analysis of prostate cancer in Sweden: support for dominant inheritance. Am J Epidemiol. 146:1997;552-557.
19. Cui J., Staples M.P., Hopper J.L., English D.R., McCredie M.R., Giles G.G. Segregation analyses of 1476 population-based Australian families affected by prostate cancer. Am J Hum Genet. 68:2001;1207-1218.
20. Schaid D.J., McDonnell S.K., Blute M.L., Thibodeau S.N. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet. 62:1998;1425-1438.
21. Smith J.R., Freije D., Carpten J.D., et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science. 274:1996;1371-1374.
22. Berthon P., Valeri A., Cohen-Akenine A., et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q422-43. Am J Hum Genet. 62:1998;1416-1424.
23. Gibbs, Stanford J.L., McIndoe R.A., et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet. 64:1999;776-787.
24. Berry R., Schroeder J.J., French A.J., et al. Evidence for a prostate cancer-susceptibility locus on chromosome 20. Am J Hum Genet. 67:2000;82-91.
25. Suarez B.K., Lin J., Burmester J.K., et al. A genome screen of multiplex sibships with prostate cancer. Am J Hum Genet. 66:2000;933-944.
26. Xu J., Zheng S. L., Hawkins G. A., et al. Linkage and association studies of prostate cancer susceptibility: evidence for linkage at 8p22-23. Am J Hum Genet. 69:2001;341-350.
27. Gronberg H., Xu J., Smith J. R., et al. Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. Cancer Res. 57:1997;4707-4709.
28. Cooney K. A., McCarthy J. D., Lange E., et al. Prostate cancer susceptibility locus on chromosome 1q: a confirmatory study. J Natl Cancer Inst. 89:1997;955-959.
29. Neuhausen S.L., Farnham J.M., Kort E., Tavtigian S.V., Skolnick M.H., Cannon-Albright L.A. Prostate cancer susceptibility locus HPC1 in Utah high-risk pedigrees. Hum Mol Genet. 8:1999;2437-2442.
30. Eeles R.A., Durocher F., Edwards S., et al. Linkage analysis of chromosome 1q markers in 136 prostate cancer families. Am J Hum Genet. 62:1998;653-658.
31. Goode E.L., Stanford J.L., Chakrabarti L., et al. Linkage analysis of 150 high-risk prostate cancer families at 1q24-25. Genet Epidemiol. 18:2000;251-275.
32. Giovannucci E., Stampfer M.J., Krithivas K., et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA. 94:1997;3320-3323.
33. Carpten J., Nupponen N., Isaacs S., et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet. 30:2002;181-184.
34. Ostrander E.A., Stanford J.L. Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet. 67:2000;1367-1375.
35. Lander E.S. The new genomics: global views of biology. Science. 274:1996;536-539.
36. Ponder B.A. Cancer genetics. Nature. 411:2001;336-341.
37. Chang B.L., Zheng S.L., Hawkins G.A., et al. Polymorphic GGC repeats in the androgen receptor gene are associated with hereditary and sporadic prostate cancer risk. Hum Genet. 110:2002;122-129.
38. Lange E.M., Chen H., Brierley K., et al. The polymorphic exon 1 androgen receptor CAG repeat in men with a potential inherited predisposition to prostate cancer. Cancer Epidemiol Biomarkers Prev. 9:2000;439-442.
39. Stanford J.L., Just J.J., Gibbs M.K., et al. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res. 57:1997;1194-1198.
40. Nam R.K., Toi A., Vesprini D., et al. V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology. 57:2001;199-204.
41. Mononen N., Ikonen T., Syrjakoski K., et al. A missense substitution A49T in the steroid 5-alpha-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br J Cancer. 84:2001;1344-1347.
42. Chang B., Zheng S.L., Isaacs S.D., et al. Linkage and association of CYP17 gene in hereditary and sporadic prostate cancer. Int J Cancer. 95:2001;354-359.
43. Haiman C.A., Stampfer M.J., Giovannucci E., et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev. 10:2001;743-748.
44. Rebbeck T.R., Walker A.H., Zeigler-Johnson C., et al. Association of HPC2/ELAC2 genotypes and prostate cancer. Am J Hum Genet. 67:2000;1014-1019.
45. Xu J., Zheng S.L., Carpten J.D., et al. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am J Hum Genet. 68:2001;901-911.
46. Coughlin S.S., Hall I.J. A review of genetic polymorphisms and prostate cancer risk. Ann Epidemiol. 12:2002;182-196.
47. Tut T.G., Ghadessy F.J., Trifiro M.A., Pinsky L., Yong E.L. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab. 82:1997;3777-3782.
48. Irvine R.A., Yu M.C., Ross R.K., Coetzee G.A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 55:1995;1937-1940.
49. Howell M.A. Factor analysis of international cancer mortality data and per capita food consumption. Br J Cancer. 29:1974;328-336.
50. Armstrong B., Doll R. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer. 15:1975;617-631.
51. Whittemore A.S., Kolonel L.N., Wu A.H., et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst. 87:1995;652-661.
52. Lee M.M., Wang R.T., Hsing A.W., et al. Case-control study of diet and prostate cancer in China. Cancer Causes Control. 9:1998;545-552.
53. Hayes R.B., Ziegler R.G., Gridley G., et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev. 8:1999;25-34.
54. Bjerve K.S., Tretli S., Jellum E., Robsahm T.E., Vatten L. Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. Int J Cancer. 71:1997;545-551.
55. Giovannucci E., Rimm E.B., Colditz G.A., et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. 85:1993;1571-1579.
56. De Stefani E., Deneo-Pellegrini H., Boffetta P., Ronco A., Mendilaharsu M. Alpha-linolenic acid and risk of prostate cancer: a case-control study in Uruguay. Cancer Epidemiol Biomarkers Prev. 9:2000;335-338.
57. Godley P.A., Campbell M.K., Miller C., et al. Correlation between biomarkers of omega-3 fatty acid consumption and questionnaire data in African American and Caucasian United States males with and without prostatic carcinoma. Cancer Epidemiol Biomarkers Prev. 5:1996;115-119.
58. Gann P.H., Hennekens C.H., Sacks F.M., Grodstein F., Giovannucci E.L., Stampfer M.J. Prospective study of plasma fatty acids and risk of prostate cancer. J Natl Cancer Inst. 86:1994;281-286.
59. Chan J.M., Stampfer M.J., Ma J., Gann P.H., Gaziano J.M., Giovannucci E.L. Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. Am J Clin Nutr. 74:2001;549-554.
60. Chan J.M., Giovannucci E., Andersson S.O., Yuen J., Adami H.O., Wolk A. Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer (Sweden). Cancer Causes Control. 9:1998;559-566.
61. Luo J., Zha S., Gage W.R., et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res. 62:2002;2220-2226.
62. Veierod M.B., Laake P., Thelle D.S. Dietary fat intake and risk of prostate cancer: a prospective study of 25 708 Norwegian men. Int J Cancer. 73:1997;634-638.
63. Augustsson K., Skog K., Jagerstad M., Dickman P.W., Steineck G. Dietary heterocyclic amines and cancer of the colon, rectum, bladder, and kidney: a population-based study. Lancet. 353:1999;703-707.
64. Stattin P., Adlercreutz H., Tenkanen L., et al. Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study. Int J Cancer. 99:2002;124-129.
65. Strom S.S., Yamamura Y., Duphorne C.M., et al. Phytoestrogen intake and prostate cancer: a case-control study using a new database. Nutr Cancer. 33:1999;20-25.
66. Severson R.K., Nomura A.M., Grove J.S., Stemmermann G.N. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 49:1989;1857-1860.
67. Kolonel L.N., Hankin J.H., Whittemore A.S., et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev. 9:2000;795-804.
68. Landstrom M., Zhang J.X., Hallmans G., et al. Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats. Prostate. 36:1998;151-161.
69. Bylund A., Zhang J.X., Bergh A., et al. Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice. Prostate. 42:2000;304-314.
70. Giovannucci E., Rimm E.B., Liu Y., Stampfer M.J., Willett W.C. A prospective study of tomato products, lycopene, and prostate cancer risk. J Natl Cancer Inst. 94:2002;391-398.
71. Chen L., Stacewicz-Sapuntzakis M., Duncan C., et al. Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. J Natl Cancer Inst. 93:2001;1872-1879.
72. Redman C., Xu M.J., Peng Y.M., et al. Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells. Carcinogenesis. 18:1997;1195-1202.
73. Redman C., Scott J.A., Baines A.T., et al. Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett. 125:1998;103-110.
74. Clark L.C., Combs G.F. Jr, Turnbull B.W., et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial Nutritional Prevention of Cancer Study Group. JAMA. 276:1996;1957-1963.
75. Clark L.C., Dalkin B., Krongrad A., et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol. 81:1998;730-734.
76. Heinonen O.P., Albanes D., Virtamo J., et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst. 90:1998;440-446.
77. Huggins C., Hodges C.V. Studies on prostatic cancer I: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate 1941. J Urol. 167:2002;948-951.
78. Hsing A.W. Hormones and prostate cancer: what's next? Epidemiol Rev. 23:2001;42-58.
79. Stattin P., Soderberg S., Hallmans G., et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab. 86:2001;1341-1345.
80. Hsing A.W., Chua S. Jr, Gao Y.T., et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst. 93:2001;783-789.
81. Chan J.M., Stampfer M.J., Giovannucci E., et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 279:1998;563-566.
82. Harman S.M., Metter E.J., Blackman M.R., Landis P.K., Carter H.B. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab. 85:2000;4258-4265.
83. Stattin P., Bylund A., Rinaldi S., et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst. 92:2000;1910-1917.
84. Hickey K., Do K.A., Green A. Smoking and prostate cancer. Epidemiol Rev. 23:2001;115-125.
85. Dennis L.K., Hayes R.B. Alcohol and prostate cancer. Epidemiol Rev. 23:2001;110-114.
86. Peterson H.B., Howards S.S. Vasectomy and prostate cancer: the evidence to date. Fertil Steril. 70:1998;201-203.
87. Lee I.M., Sesso H.D., Chen J.J., Paffenbarger R.S. Jr. Does physical activity play a role in the prevention of prostate cancer? Epidemiol Rev. 23:2001;132-137.
88. Fleshner N.E., Kucuk O. Antioxidant dietary supplements: rationale and current status as chemopreventive agents for prostate cancer. Urology. 57:2001;90-94.
89. Lieberman R. Prostate cancer chemoprevention: strategies for designing efficient clinical trials. Urology. 57:2001;224-229.
90. Coltman C.A. Jr, Thompson I.M. Jr, Feigl P. Prostate Cancer Prevention Trial (PCPT) update. Eur Urol. 35:1999;544-547.
91. Klein E.A., Thompson I.M., Lippman S.M., et al. SELECT: the next prostate cancer prevention trial Selenium and Vitamin E Cancer Prevention Trial. J Urol. 166:2001;1311-1315.